Researchers Present Data from Second Validation Study of Genomic Health Oncotype DX DCIS Test | GenomeWeb

SAN ANTONIO — In a large cohort of patients from Ontario with ductal carcinoma in situ (DCIS), Genomic Health's Oncotype DX DCIS score accurately assessed the 10-year risk of local and invasive local recurrence for those treated with breast conservation surgery, researchers at the San Antonio Breast Cancer Symposium reported.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

Sponsored by
Agilent Technologies

In this online seminar, speakers from the Center for Personalized Diagnostics at Penn Medicine will discuss the design and technical validation of a custom next-generation sequencing panel to detect mutations in a wide array of tumor types.

Sponsored by

This webinar will discuss a partnership model for noninvasive prenatal testing that enabled LifeLabs Genetics, a genetic testing lab based in Toronto, Ontario, to implement NIPT in house.